Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
Article in Cell Reports (April 2022)
The most recent citing publications are shown below. View all 39 publications that cite this research output on Dimensions.
Article in Cell Reports (April 2022)
Article in Drugs (December 2021)
Article in Genes (September 2021)